Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586975 · ClinicalTrials.gov registry record · Phase 2
Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01586975 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 93 participants.
The verdict
NCT01586975, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
Interventions
- DRUG Clopidogrel
- DRUG Aspirin 81 mg
- DRUG Aspirin >300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01586975
The ClinicalTrials.gov registry entry for NCT01586975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Clopidogrel is the first listed.
NCT01586975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01586975 about?
NCT01586975 is a clinical study titled "Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events". The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
What is the current status of trial NCT01586975?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2007-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01586975?
The interventions under investigation include: Clopidogrel (DRUG), Aspirin 81 mg (DRUG), Aspirin >300 mg (DRUG).
Who is sponsoring clinical trial NCT01586975?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.